HARVARD BIOSCIENCE INC

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

HBIO$9.26+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Revenues	$22,727	$20,450	$43,482	$42,224
Cost of revenues	10,097	8,917	18,608	18,507
Gross profit	12,630	11,533	24,874	23,717
Sales and marketing expenses	5,400	4,539	10,735	9,510
General and administrative expenses	4,617	4,262	9,319	9,447
Research and development expenses	2,453	2,189	4,779	4,510
Amortization of acquired intangible assets	820	1,162	1,640	2,322
Goodwill impairment - Note 4	-	-	-	47,951
Other operating expenses - Note 1	318	200	553	464
Total operating expenses	13,608	12,352	27,026	74,204
Operating loss	(978)	(819)	(2,152)	(50,487)
Other expense:
Interest expense	(1,793)	(1,001)	(3,521)	(1,934)
Other expense, net	(125)	(434)	(530)	(627)
Total other expense	(1,918)	(1,435)	(4,051)	(2,561)
Loss before income taxes	(2,896)	(2,254)	(6,203)	(53,048)
Income tax expense (benefit)	14	28	131	(426)
Net loss	$(2,910)	$(2,282)	$(6,334)	$(52,622)
Loss per share:
Basic and diluted loss per share *	$(0.64)	$(0.52)	$(1.41)	$(11.91)
Weighted-average common shares:
Basic and diluted *	4,526	4,430	4,484	4,420

*	Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026.

HARVARD BIOSCIENCE, INC.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.